Patents Examined by Elizabeth C. Weimar
  • Patent number: 5082670
    Type: Grant
    Filed: December 15, 1988
    Date of Patent: January 21, 1992
    Assignee: The Regents of the University of California
    Inventors: Fred H. Gage, Michael B. Rosenberg, Theodore Friedmann
  • Patent number: 5082785
    Abstract: A process of producing 2-keto-L-gulonic acid from sorbose via a recombinant bacteria including expression vectors and probes for producing said recombinant bacteria.
    Type: Grant
    Filed: January 30, 1987
    Date of Patent: January 21, 1992
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ronald F. Manning, Maria S. Kahn
  • Patent number: 5082779
    Abstract: A method of expressing a non-prolactin gene in a transgenic animal, said expression occurring essentially only after birth and essentially only in the pituitary cells of said animal, which comprises (a) operably linking said gene to a prolactin promoter to form a transcriptional unit, and (b) introducing said unit into one or more cells of said animal.
    Type: Grant
    Filed: August 6, 1987
    Date of Patent: January 21, 1992
    Assignee: Edison Animal Biotechnology Center/Ohio University
    Inventors: Fritz Rottman, Sherron Helms
  • Patent number: 5082782
    Abstract: A method for producing horseshoe crab amebocytes in vitro by isolating amebocyte producing tissue from the gill flaps of horseshoe crabs, especially Limulus polyphemus. In contrast to all previous attempts to isolate and culture amebocytes from Limulus for the production of pyrogen-sensitive lysate, an effective method and means has been developed utilizing the discovery that the gill flaps are the source of the cells which differentiate into competent amebocytes. Once isolated, the tissue can be cultured long term in vitro on an artificial surface or as part of the gill flap leaflets, opened along one edge to allow access of the media to the developing amebocytes. Amebocytes are removed from the gill flaps by pulsing with Limulus serum, copper sulfate, detergent, or combinations thereof.
    Type: Grant
    Filed: December 27, 1988
    Date of Patent: January 21, 1992
    Assignee: Worcester Polytechnic Institute
    Inventors: Daniel G. Gibson, III, Joan B. Hilly
  • Patent number: 5082775
    Abstract: The present invention relates to the isolation and restoration of biological activity to inactive proteins, that is solubilizing, renaturing and restoring activity to proteins which have been partially denatured or inactivated, e.g. during their synthesis in a host cell, such as E. coli, or during isolation. In particular this invention relates to both a means for extracting insoluble eukaryotic proteins from bacteria and to an efficient process for producing active chymosin from an insoluble chymosin precursor isolated from genetically engineered bacteria.
    Type: Grant
    Filed: October 28, 1988
    Date of Patent: January 21, 1992
    Assignee: Berlex Laboratories, Inc.
    Inventors: Michael T. McCaman, John F. King
  • Patent number: 5082774
    Abstract: An expression vector replicable in a mammalian cell includes a prepro-NGF encoding DNA sequence operably linked with regulatory DNA capable of effecting the expression of the prepro-NGF encoding DNA sequence in the cell. Also, a mammalian cell is transfected with such an expression vector. Also, a method for making recombinant human nerve growth factor includes transfecting a mammalian cell with such an expression vector, maintaining the cell in a culture medium, and isolating recombinant human nerve growth factor from the medium. Also, a composition includes recombinant human nerve growth factor made according to such a method combined with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 30, 1988
    Date of Patent: January 21, 1992
    Assignee: The General Hospital Corporation
    Inventor: Gerhard Heinrich
  • Patent number: 5081030
    Abstract: The present invention comprises a process for release from the cell-receptor complex of positively selected cells in viable, functional condition, where a ligand involved in the particular receptor-ligand interaction utilized for the affinity purification is selectively attacked by one or more degradative enzymes specific for that ligand. A resulting cell suspension can be obtained substantially free of receptor material.This invention, in one embodiment, contemplates a method for positive stem cell selection, utilizing anti-MY10 and immunomagnetic microspheres to isolate CD34-positive marrow cells and employing an enzyme to release micropheres from the isolated CD34-positive cells. Reproducible enzymatic cleaving of immunomagnetic microspheres from MY10-positive cells can be achieved by brief treatment of the preparation with papain or chymopapain. The isolated CD34-positive cells are particularly desirable for bone marrow transplantation.
    Type: Grant
    Filed: April 25, 1989
    Date of Patent: January 14, 1992
    Assignee: The Johns Hopkins University
    Inventor: Curt I. Civin
  • Patent number: 5081031
    Abstract: A polypeptide having the following formula is provided: leu-ala-gly-ser-cys-leu-ala-arg-phe-ser-thr-met which can bind heparin and promote cellular adhesion. Medical devices such as prosthetic implants, percutaneous devices and cell culture substrates coated with a composition including the polypeptide are also provided.
    Type: Grant
    Filed: December 14, 1989
    Date of Patent: January 14, 1992
    Assignee: Regents of the University of Minnesota
    Inventors: Photini-Effie C. Tsilibary, Leo T. Furcht
  • Patent number: 5079165
    Abstract: Methods and compositions are provided for the cloning and expression of plasmids bearing genes coding for the non-toxic subunit of the heat-laible enterotoxin (LT-B) of E. coli. These plasmids may be cloned into stable avirulent strains of Salmonella typhi and used to make oral bivalent vaccines. Such vaccines may be used to prevent typhoid fever and cholera-like enterotoxin-induced diarrheal disease.
    Type: Grant
    Filed: June 29, 1988
    Date of Patent: January 7, 1992
    Assignee: Praxis Biologics, Inc.
    Inventors: John D. Clements, Sawsan E. El-Morshidy
  • Patent number: 5079152
    Abstract: A phosphorus-containing analog-ligand having a stereoconfiguration that substantially corresponds to the stereoconfiguration of an amide- or ester-forming transition state is used to induce production of receptor molecules whose antibody combining sites have stereospecific amide or ester synthase catalytic activity when reacted with a ligand containing (i) a carbonyl carbon atom and (ii) an amine or alcohol group that are structurally capable of forming a preselected stereoisomer of a carboxylic amide or ester.
    Type: Grant
    Filed: August 7, 1987
    Date of Patent: January 7, 1992
    Assignee: Scripps Clinic and Research Foundation
    Inventors: Stephen Benkovic, Richard A. Lerner, Alfonso Tramontano, Andrew D. Napper
  • Patent number: 5079160
    Abstract: A method to obtain purified, well-defined cell populations from intact organs uses digestion of the distended organ with suitable proteolytic enzymes and harvest of the cell subpopulation by screening the effluent from treatment of the organ with physiologically compatible medium by a filtration screen permitting the passage of the desired cells or clusters of cells, but preventing the passage of larger particles. In this manner, physical/mechanical disruption of the cell population is unnecessary, and the cells or clusters are eased out of their structural matrix and harvested directly. Application of this method to the preparation of purified Islets of Langerhans from intact pancreas is described.
    Type: Grant
    Filed: June 8, 1987
    Date of Patent: January 7, 1992
    Inventors: Paul E. Lacy, David W. Scharp, Camillo Ricordi
  • Patent number: 5077211
    Abstract: Methods for purifying DNA repair enzymes are provided in which an aqueous solution of a DNA repair enzyme in an impure state is applied to a molecular sieve column having an exclusion limit which will retard the DNA repair enzyme but will not retard contaminants larger than the DNA repair enzyme. The DNA repair enzyme in an enhanced state of purity is eluted isocratically from the molecular sieve column in an elution buffer and applied directly to a DNA affinity column in the same buffer without intermediate dialysis, ultrafiltration, or other procedures. The DNA repair enzyme is eluted from the DNA affinity column using, for example, a salt gradient. The method is rapid, inexpensive, simple to perform, and has been found to produce a homogeneous final product. In accordance with other aspects of the invention, the purified DNA repair enzymes are encapsulated in liposomes and administered to living cells in situ.
    Type: Grant
    Filed: July 6, 1988
    Date of Patent: December 31, 1991
    Assignee: Applied Genetics, Inc.
    Inventor: Daniel B. Yarosh
  • Patent number: 5075229
    Abstract: A transgenic animal is constructed in which one or more cells contain a promoter to the gene for cytosolic PEPCK operably linked to a non-PEPCK gene of interest. Expression of this gene is controlled by modifying the protein and carbohydrate components of the animal's diet, or by direct hormonal regulation. The PEPCK promoter is induced by high protein and inhibited by high carbohydrate, or more directly by cAMP and insulin. The linked gene is expressed essentially only after bith and essentially only in particular tissues. The PEPCK promoter has a extremely high promoter strength.
    Type: Grant
    Filed: June 13, 1988
    Date of Patent: December 24, 1991
    Assignee: Ohio University Edison Animal Biotechnology Center
    Inventors: Richard W. Hanson, Mary McGrane, Jay Short, Maria Hatzoglou
  • Patent number: 5075232
    Abstract: The present invention is directed to a method for cloning and producing the NlaIV restriction endonuclease by 1) introducing the restriction endonuclease gene from N. lactamica NRCC 2118 into a host whereby the restriction gene is expressed; 2) fermenting the host which contains the vector encoding and expressing the NlaIV restriction endonuclease, and 3) purifying the NlaIV restriction endonuclease from the fermented host which contains the vector encoding and expressing the NlaIV restriction endonuclease activity.
    Type: Grant
    Filed: July 28, 1988
    Date of Patent: December 24, 1991
    Assignee: New England Biolabs, Inc.
    Inventor: Richard D. Morgan
  • Patent number: 5075230
    Abstract: A plasminogen activator precursor obtainable from a serum-free culture fluid of human kidney cells is stabilized by adding to its solution poly-C1-C5-alkylene glycols, polyethylene-polyoxypropylene copolymers, mandelic acid salts, triethanolamine, acid addition salts of acetylglycillysine methyl ester, guanidine salts, thiocyanic acid salts, alkali metal iodides or serine.
    Type: Grant
    Filed: April 20, 1990
    Date of Patent: December 24, 1991
    Assignee: The Green Cross Corporation
    Inventors: Kazuo Morimoto, Motoshi Sagane, Kazuhiro Ohara, Shusaku Narita
  • Patent number: 5075231
    Abstract: Process for the preparation of a gastric lipase. The stomachs of rabbits or horses undergo extraction by an acid aqueous medium, the lipase extract is salted out by the addition of hydrosoluble salts then, by filtration on a molecular sieve, followed by separation using ion exchange chromatography, an elution fraction containing the lipase is collected.Medicament for fighting against malabsorptions of fatty substances.
    Type: Grant
    Filed: September 17, 1987
    Date of Patent: December 24, 1991
    Assignee: Jouveinal S.A.
    Inventors: Herve Moreau, Robert Verger, Daniel Lecat, Jean-Louis Junien
  • Patent number: 5073492
    Abstract: A method for synergistically enhancing endothelial cell growth in an appropriate environment therefor which comprises adding to the environment, VEGF, effectors and serum-derived factor. A formulation for synergistically enhancing endothelial cell growth comprising VEGF, uridine, thymidine and serum-derived factor is also disclosed.
    Type: Grant
    Filed: January 9, 1987
    Date of Patent: December 17, 1991
    Assignee: The Johns Hopkins University
    Inventors: Chung-Ho Chen, Sumi C. Chen
  • Patent number: 5073490
    Abstract: Tissue cell culture preparations derived from the cells of a transgenic animal are disclosed. These tissue cell preparations are capable of expressing a non-analogous gene product, i.e., a gene product which is not naturally produced by the animal cells.Transhybridomas, i.e., hybridomas and immortalized cells created using cells obtained from transgenic animals, and methods for creating these transhybridomas are also disclosed. In particular, two transhybridomas, A 15.9 and B 6.4, both capable of producing human growth hormone, have been disclosed.
    Type: Grant
    Filed: February 27, 1990
    Date of Patent: December 17, 1991
    Assignee: Institut Pasteur
    Inventors: Charles Babinet, Dominique Morello
  • Patent number: 5073677
    Abstract: The invention relates to plant cells and dicotyledonous plants transformed with chimeric rat glutathione-S-transferase gene constructs. Transgenic tobacco plants and progeny expressed the chimeric gene constructs under the control of a plant promoter. The transgenic plants and progeny demonstrated resistance to a herbicide which is normally inhibitory to plants not expressing the chimeric construct.
    Type: Grant
    Filed: August 4, 1989
    Date of Patent: December 17, 1991
    Assignees: Ciba-Geigy Corporation, The Pennsylvania Research Corporation
    Inventors: Georgia Helmer, John Duesing, Steven Rothstein, Liliana Scarafia, Mary-Dell Chilton, Hui-Chen J. Lai, Chen-Pei D. Tu
  • Patent number: 5073675
    Abstract: This invention relates to the discovery that the prokaryotic enzyme, aminoglycoside 3"-adenyltransferase (AGAT), in particular as encoded by a bacterial aadA gene, is useful as a selectable marker for transformed plants. The enzyme conveys resistance to spectinomycin and streptomycin. Such markers are particularly advantageous because they are non-lethal, provide rapid visual identification of transformed cells and permit selection in media containing either spectinomycin or streptomycin. In addition, AGAT may be used as a selectable marker which differentiates by enabling survival on selective media.
    Type: Grant
    Filed: May 26, 1989
    Date of Patent: December 17, 1991
    Assignee: DNA Plant Technology Corporation
    Inventors: Jonathan Jones, Pal Maliga